Sökning: "Björn Wettermark"

Visar resultat 1 - 5 av 7 avhandlingar innehållade orden Björn Wettermark.

  1. 1. Drug utilization 90% : using aggregate drug statistics for the quality assessment of prescribing

    Författare :Björn Wettermark; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Drug sales statistics; drug utilization; feedback general practitioners; guidelines; indicators; intervention; prescribing; quality indicators;

    Sammanfattning : Introduction: There is room for improvement in prescribing. Although a range of indicators have been developed to assess the quality of prescribing, none of them focus on all drugs and there is a gap between what is credible for health care professionals and what can be achieved with the readily available data. LÄS MER

  2. 2. Real-Time Monitoring of Healthcare Interventions in Routine Care : Effectiveness and Safety of Newly Introduced Medicines

    Författare :Thomas Cars; Johan Sundström; Björn Wettermark; Martin Neovius; Til Stürmer; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Electronic Health Records; Comparative Effectiveness Research; Comparative Safety Research; Sequential drug monitoring; propensity score; real-world data; infliximab; TNF-inhibitors; dronedarone; amiodarone; flecainide; Farmakoepidemiologi; Pharmacoepidemiology;

    Sammanfattning : Before market authorization of new medicines, their efficacy and safety are evaluated using randomized controlled trials. While there is no doubt about the scientific value of randomized trials, they are usually conducted in selected populations with questionable generalizability to routine care. LÄS MER

  3. 3. Surveys and services : The feasibility of conducting research in Swedish community pharmacies

    Författare :Pia Frisk; Sofia Kälvemark-Sporrong; Margareta Hammarlund-Udenaes; Björn Wettermark; Marcel L Bouvy; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacy; Community pharmacy; Pharmaceutical services; Drug utilization research; Survey; Patient; Pharmaceutical care; Feasibility; Sweden; Social Pharmacy; Samhällsfarmaci;

    Sammanfattning : For the past decades, there has been a shift in community pharmacy practice from dispensing and compounding towards provision of pharmacy services. Research is important to generate evidence for new services within pharmacy practice. LÄS MER

  4. 4. On drug use, multiple medication and polypharmacy in a national population

    Författare :Bo Hovstadius; Göran Petersson; Sven Tågerud; Bengt Åstrand; Björn Wettermark; Linnéuniversitetet; []
    Nyckelord :drug use; multiple medication; polypharmacy; register; prevalence; therapeutic intensity; acquisition cost.; NATURAL SCIENCES; NATURVETENSKAP; Biomedical Sciences; Biomedicinsk vetenskap;

    Sammanfattning : The application of multiple medications has successively increased during a number of years and has thereby increased the potential risks of adverse drug reactions, interactions and non-adherence to drug therapy. This may result in unnecessary health expenditure, directly due to redundant drug sales, and indirectly due to the increased hospitalization caused by drug-related problems. LÄS MER

  5. 5. Bridging the gap between clinical trials and clinical practice : sacubitril-valsartan in heart failure as a model

    Författare :Helena Norberg; Krister Lindmark; Ellinor Bergdahl; Eva-Lotta Glader; Björn Wettermark; Umeå universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Systematic implementation; healthcare quality improvement; chronic disease management; heart failure; sacubitril-valsartan; real-world population; sex differences; kardiologi; Cardiology;

    Sammanfattning : When novel treatments prove more effective than standard therapies, a swift and effective implementation is needed to reach cost-effectiveness and to benefit eligible patients. Meanwhile, women and elderly are often under-represented in clinical trials, which creates a knowledge gap on how to optimize treatment in clinical practice. LÄS MER